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ABSTRACT: Bioﬁlms are often associated with human
bacterial infections, and the natural tolerance of bioﬁlms to
antibiotics challenges treatment. Compounds with anti-
bioﬁlm activity could become useful adjuncts to antibiotic
therapy. We used norspermidine, a natural trigger for
bioﬁlm disassembly in the developmental cycle of Bacillus
subtilis, to develop guanidine and biguanide compounds
with up to 20-fold increased potency in preventing bioﬁlm
formation and breaking down existing bioﬁlms. These
compounds also were active against pathogenic Staph-
ylococcus aureus. An integrated approach involving
structure−activity relationships, protonation constants,
and crystal structure data on a focused synthetic library
revealed that precise spacing of positively charged groups
and the total charge at physiological pH distinguish potent
bioﬁlm inhibitors.
M
ost bacteria form bioﬁlms, which are multicellular
microbial communities embedded in a self-produced
exopolymeric substance (EPS) largely composed of a protein
anchor and diﬀerent extracellular polymers. Bacteria within a
mature bioﬁlm community exist in an altered metabolic state
and diﬀerent physical environment than their free-ﬂoating, or
planktonic, relatives. Bioﬁlm bacteria generally tolerate anti-
biotic treatment,
1,2 and antibiotics can induce bioﬁlm
formation.
3,4 Consequently, bioﬁlm inhibitors can be applied
to decrease antibiotic tolerance of bacteria.
5 Bioﬁlms play a
major role in many bacterial infections.
2 In humans, the
antibiotic tolerance of bioﬁlm communities frustrates the
treatment of persistent bacterial infections such as those
associated with cystic ﬁbrosis, endocarditis, joint prostheses,
heart catheters, and replacement heart valves.
6,7
In response to this challenge, high-throughput assays have
been developed to identify small molecules with the ability to
prevent bioﬁlm formation or disrupt existing bioﬁlms.
8 We
recently explored an alternative strategy that exploits the
normal developmental cycle of bacteria. Bioﬁlms form when
planktonic bacteria in the aqueous phase aggregate on a solid
surface or at an air−liquid interface. The bioﬁlm colony grows
both by recruitment and cell division to form a mature colony.
Mature colonies eventually disintegrate, and the dispersed
bacteria resume a planktonic lifestyle (Figure 1). Bacterially
produced small molecules orchestrate the creation and
disintegration of bioﬁlms, and identifying these molecular
signals could lead to therapeutically useful templates.
We previously identiﬁed D-amino acids as potent bioﬁlm
disruptors because of their ability to release the protein
component of EPS from the bacterial cell wall.
9 Recently we
identiﬁed norspermidine as a key disruptor of the polymeric
component of EPS.
10 Mixtures of norspermidine with D-amino
acids were found to be highly synergistic (single-digit
nanomolar) in disrupting bioﬁlms (Figure 1).
10 Here we report
synthetic mimics of norspermidine with increased potency and
a structure-based rationale for their activity.
Norspermidine appears to disrupt bioﬁlms by targeting the
extracellular component of EPS in Bacillus subtilis, and it
seemed likely that it does so by binding to negatively charged
or possibly neutral groups using Coulombic attraction and
hydrogen bonding as important features.
10 We tested a set of
commercially available polyamines. Norspermidine was most
active in inhibiting bioﬁlms for B. subtilis and Staphylococcus
aureus, followed by norspermine, which has an additional
aminopropyl unit in its structure [Figure S1 and Table S2 in the
Supporting Information (SI)]. Perhaps surprisingly, spermi-
dine, with one longer aminobutyl residue in place of an
aminopropyl unit, and diethylenetriamine, with two shorter
aminoethyl groups, were inactive in both species. This sharp
length dependence indicated that matching the NH-to-NH
distance of the (poly)propyleneamine motif of norspermidine
and norspermine (4.9 Å) to the pitch of various helical EPS
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Figure 1. Stages in the developmental cycle of bioﬁlm formation and
disruption. Norspermidine both prevents the formation of new
bioﬁlms and collapses the structure of existing bioﬁlms.
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(4.6−5.3 Å; Table S1) is a key feature. Binding of these
polyamines to negatively charged secondary structures would
neutralize the charge and collapse the aqueous meshwork
characteristic of mature bioﬁlms.
10 This simple model involving
three or four positively charged groups separated by propyl
units could be tested against bioﬁlm formation of B. subtilis with
synthetic mimics, and guanidines and biguanides emerged as
particularly appealing substitutes for polyamines because of
their potentially increased overall charge at physiological pH
values.
We used three diﬀerent synthetic strategies to generate a
small library of compounds with guanidinyl or biguanidyl
groups as chloride or sulfate salts (Figure 2). Guanidines can be
conveniently prepared from amines with S-methylisothiourea
(Scheme 1),
11 and that reagent aﬀorded terminal guanidines (1,
2, 4, 5, 7−9, and 12) from commercially available primary
amines. Alternatively, cyanamide (or the alkylated form of its
carbodiimide tautomer), which reacts with secondary amines
(Scheme 1),
12 was used to prepare triguanidinylated com-
pounds (3 and 6) and alkylated guanidines (3 and 10). Finally,
a biguanide (11) was synthesized from m-phenylenediamine
and dicyandiamide (Scheme 1) according to Cohn.
13 While
aromatic amines are known to react readily with dicyandia-
mide,
13 our attempts to extend the reaction to primary aliphatic
amines were unsuccessful.
Compounds were tested for inhibition of bioﬁlm formation
in B. subtilis, the model organism that led to norspermidine,
10
and S. aureus as a related pathogenic species with high clinical
relevance. The minimum bioﬁlm inhibitory concentrations
(MBICs) for all of the compounds are given in Table S2. Some
of the compounds exhibited remarkable activity for the
inhibition of bioﬁlms, with 5−20-fold increased activity toward
B. subtilis and >8-fold increased activity toward S. aureus relative
to norspermidine (Figure 3A and Tables 1 and S2). In addition
to preventing bioﬁlm formation, the most potent compound
was also able to disrupt existing bioﬁlms (Figure 3B). Early on,
it became clear that the counterion of the amine or guanidine
had a signiﬁcant eﬀect on the activity. For instance, the free
base of norspermidine was 3 times more active than the
chloride salt, which in turn was 3 times more active than the
sulfate salt in the B. subtilis assay (Table S2). Therefore, we
generated the free bases of selected compounds and compared
them with the corresponding salts. For B. subtilis, a free base’s
activity for bioﬁlm inhibition was greater than or equal to that
of the salt, while for S. aureus there was no clear trend.
Solubility products (Ks) showed no correlation with the activity
of the compounds (Table S3), and bioavailability and delivery
into the bioﬁlm matrix are probably critical parameters. None
of the compounds signiﬁcantly inhibited bacterial growth at or
close to its corresponding MBIC value, ruling out the
possibility that bioﬁlm inhibition was an artifact of reduced
viability (see the SI). Only compound 7 started to aﬀect growth
in B. subtilis at concentrations above 200 μM, which is 40 times
its MBIC.
In B. subtilis, the most active compounds were 6, 7, 8, 10, and
11 (as salts and bases; Tables 1 and S2), with MBICs between
Figure 2. Library of synthetic guanidinylated or biguanidylated
polyamine analogues. For free bases, “base” appears in the “form”
column; for salts, the counterion is given (for stoichiometry, see the
SI).
Scheme 1
Figure 3. Enhanced activity of synthetic compounds 6a, 7a, and 11a
against B. subtilis. (A) Inhibition of bioﬁlm formation relative to the
corresponding polyamines. (B) Breakdown of pre-existing bioﬁlms
within 12 h. Norspd, norspermidine; Norspn, norspermine; PBS,
phosphate-buﬀered saline.
Table 1. Activities of Selected Compounds
MBIC (μM) at pH 7.4
compound B. subtilis S. aureus
4 >1000 50
5a 500 75
5b 375 ± 125 400
6a 10
a >1000 (500
a)
6b 10 50
7a 55 5 ± 15
7b 2 250
9 100 500
10 30 20 ± 10
11a 30 300
11b 7 ± 3 750 ± 250
aIncomplete inhibition.
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exhibited the proposed binding motif
10 of three to four amino
or guanidine groups formally separated by propyl chains (5−7,
10, and 11; Tables 1 and S2). Additionally, the shorter
compound 9 having only a single propyl chain displayed activity
only at 100 μM. The activity pattern for S. aureus was slightly
diﬀerent, as the minimal motif required for activity was two
guanidine groups or one amino group and one guanidine group
separated by a propyl chain (4−11). Compounds with ethyl
instead of propyl chains (1−3 and 12) were inactive (≥1 mM)
for B. subtilis and only weakly active (750 μM) or inactive for S.
aureus. Biguanide itself was inactive for both species (Tables 1
and S2).
The most active inhibitors of bioﬁlm formation by S. aureus
were 4, 5a, 6b, 7a, and 10, with MBICs in the range 10−75 μM.
The activities of the best bioﬁlm inhibitors in this initial library
are comparable to the lower range of what has been reported in
the literature for bioﬁlm inhibitory compounds that do not
adversely aﬀect bacterial growth.
8
Our results support a model in which the binding of
polyamine-based inhibitors to the exopolymer depends on the
correct spacing of multiple amino or guanidine groups. The
structure−activity relationship in this library further indicates
that although there is a common motif in the two species, the
composition and structure of bioﬁlms of S. aureus and B. subtilis
are diﬀerent and allow customized inhibition of bioﬁlm
formation.
In addition to the structural properties described above, the
charge of the compounds could be an important contributor to
their inhibitory activity.
10 To investigate this possibility, we
determined the pKa values of selected compounds at 25 °C and
25 mM. Cumulative association constants were calculated by
HypNMR
14,15 (Figures S2−S11), and values for pKa(D2O)
were ﬁnally converted to pKa(H2O).
16 The pKa values for the
compounds are given in Table 2. For comparison, similar pKa
values have been reported previously for spermidine (pKa1 =
10.90, pKa2 = 9.71, and pKa3 = 8.25).
17
Speciation data derived from the pKa values were generated
using the program HySS (Figures S12−S14), and the average
charge was plotted against pH for each molecule (Figure 4).
For convenience, protonation states will be given by a string of
digits, with 1 for a protonated site and 0 for a nonprotonated
site. In this notation, the fully protonated state of
norspermidine is denoted as (111). Diethylenetriamine
(DET) has one extremely low protonation constant of 3.9
that results in one amino group being uncharged [protonation
state (101)] in the wide pH range of 5−8 (Figure 4A).
Although guanidine groups in the related structure 2
signiﬁcantly increase the third pKa value to 6.3, the central
amino group remains unprotonated at physiological pH (101),
as conﬁrmed by X-ray structure analysis (Figure S17).
The lack of activity of 2 at pH 7 reﬂects both structural and
charge liabilities. Not surprisingly, guanidine groups on the
scaﬀold of norspermidine or norspermine increased all of the
individual pKa values relative to those of the corresponding
p o l y a m i n e s( F i g u r e4 A )c a u s i n gt h ea v e r a g ed e g r e eo f
protonation to rise, which is in line with the increased activity
of 6 over norspermidine and 7 over norspermine. However,
while 5 was active, it did not display increased activity over
norspermidine, despite its higher degree of protonation (Figure
S16). On average, norspermine carries 3.3 positive charges at
pH 7, corresponding to ∼30% fully charged (1111) molecules
and the rest triply charged [(1110) or (1101)], with the
protonation microstate (1101) having one noncharged
secondary amine as the likely predominant species.
15,17,18 The
(1101) species does not comply with the triply charged (111)
motif and may contribute to the higher activity of
norspermidine over norspermine.
The active compound 11 exists at maximum in a doubly
protonated form because of its high pKa values, and this form is
virtually the only relevant species until pH 8.5 (Figure S16). In
the literature, the structure and protonation of biguanides is
frequently misrepresented, as reported by Bharatam et al.,
19
whose computational studies indicated that the central nitrogen
of a biguanide is not bonded to a hydrogen in either neutral or
charged states (Figure 4B,C). This N atom is partially
negatively charged, while the positive charge is delocalized
between the terminal nitrogen atoms of the biguanide. The
crystal structure of protonated 11 conﬁrmed these results
(Figures 4D and S19), making 11 analogous to the (1111)
motif of fully charged compound 7, which explains its activity.
Table 2. pKa values of selected compounds
compound pKa1 pKa2 pKa3 pKa4
norspermidine 11.1 ± 0.1 9.4 ± 0.2 7.1 ± 0.0 −
norspermine 10.6 ± 0.3 10.5 ± 0.3 8.7 ± 0.2 6.7 ± 0.1
spermidine 11.1 ± 0.1 9.8 ± 0.1 7.8 ± 0.1 −
DET
a 11.6 ± 0.1 9.0 ± 0.3 3.9 ± 0.1 −
1 13.6 ± 0.1 12.6 ± 0.2 −−
2 13.5 ± 0.0 12.8 ± 0.2 6.3 ± 0.0 −
4 13.7 ± 0.1 13.0 ± 0.3 −−
5 13.4 ± 0.1 12.0 ± 0.3 8.4 ± 0.1 −
6 13.8 ± 0.2 13.2 ± 0.3 12.7 ± 0.5 −
7 13.5 ± 0.1 12.0 ± 0.3 9.8 ± 0.1 7.6 ± 0.1
8 13.6 ± 0.0 12.2 ± 0.1 9.2 ± 0.1 −
9 13.6 ± 0.1 9.4 ± 0.1 −−
11 12.1 ± 0.1 10.6 ± 0.1 −−
aDiethylenetriamine.
Figure 4. Protonation and charge states. (A) Average degree of
protonation of polyamines and corresponding di- or triguanidines as a
function of pH. (B) Classical, incorrect representation of protonated
biguanides. (C) Correct protonation state for 11. (D) Biguanide
moiety cropped from the crystal structure of 11.
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activity, we determined the bioﬁlm inhibition in a pH-
dependent assay that should directly aﬀect the average charge
state of the assayed compounds. We plotted MBIC values in B.
subtilis and S. aureus assays against the calculated degree of
protonation (Figure 5). Although bioﬁlm morphology and
physiology as well as the bioavailability of the compounds are
expected to change with pH, the potency of active compounds
correlated well with the degree of protonation. For all of the
active compounds, the activity generally increased (lower
MBIC) for both species at higher protonation states, while the
inactive compound 2 did not respond to changes in
protonation. The absolute activities of diﬀerent compounds,
however, did not coincide with the degree of protonation,
suggesting that a combination of structure and charge
determine the biological activity.
In conclusion, chemical synthesis generated a focused library
of guanidine and biguanide compounds that mimic norspermi-
dine structurally and in some cases functionally with an ability
to inhibit bioﬁlm formation in B. subtilis and S. aureus. The best
compound also mimicked norspermidine’s ability to disrupt a
mature bioﬁlm. A detailed investigation of structure−activity
relationships involving protonation constants and crystal
structure data provided insights into the ways that charge and
spacing between positively charged groups aﬀect biological
activity.
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